Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FORADIL CERTIHALER vs AEROLATE SR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Formoterol is a long-acting beta2-adrenergic receptor agonist that stimulates intracellular adenyl cyclase, increasing cyclic AMP production and causing bronchodilation.
AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.
Long-term maintenance treatment of asthma,Prevention of exercise-induced bronchospasm,Maintenance treatment of chronic obstructive pulmonary disease (COPD)
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
One inhalation (12 mcg) twice daily via oral inhalation.
400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.
The terminal elimination half-life of formoterol (active component) ranges from 5 to 10 hours following inhalation. This supports twice-daily dosing, though clinical effect may persist longer due to prolonged receptor binding.
Terminal elimination half-life 12 hours (range 10–15 h) in adults; prolonged in hepatic impairment (up to 24 h) and elderly.
Formoterol is extensively metabolized by direct glucuronidation via UGT1A1, UGT1A3, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT2B7, and UGT2B15, and O-demethylation via CYP2D6 and CYP2C19.
Primarily hepatic via cytochrome P450 enzymes (CYP1A2, CYP2E1, and CYP3A4). Theophylline is metabolized to 1,3-dimethyluric acid, 1-methyluric acid, and 3-methylxanthine.
After oral inhalation, the majority of a dose is excreted in feces (up to 70%) as unchanged drug and metabolites via biliary elimination. Renal excretion accounts for approximately 13-25% of the dose, primarily as metabolites. Unabsorbed drug accounts for the remainder.
Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; 10% as unchanged in feces.
Formoterol is approximately 60-70% bound to plasma proteins (primarily albumin).
55–65% bound to plasma proteins, primarily albumin.
The volume of distribution (Vd) of formoterol is approximately 3.4 L/kg, indicating extensive distribution into tissues beyond plasma.
0.4–0.6 L/kg, indicating distribution into total body water.
Inhaled bioavailability is highly variable, approximately 20-30% of the inhaled dose reaches the lungs. Oral bioavailability is low (<10%) due to first-pass metabolism. The swallowed portion contributes minimally to systemic levels.
Oral: 90–100% for sustained-release formulation; food decreases rate but not extent (AUC unchanged).
No dosage adjustment required for renal impairment. Use with caution in severe impairment.
No dose adjustment required for renal impairment.
No dosage adjustment recommended; pharmacokinetics unaffected by mild to moderate hepatic impairment.
Use with caution in severe hepatic impairment (Child-Pugh class C); consider dose reduction by 50%.
For children 5 years and older: one inhalation (12 mcg) twice daily. Safety and efficacy in children under 5 not established.
Children 6-12 years: 200-400 mcg inhaled twice daily. Children over 12 years: same as adult dose.
No specific dose adjustment; monitor for adverse effects due to potential age-related comorbidities.
Start at lower end of dosing range (400 mcg twice daily) and titrate to response; monitor for systemic effects.
Long-acting beta2-adrenergic agonists increase the risk of asthma-related death; Foradil should only be used as add-on therapy for patients not adequately controlled on other asthma controllers or whose disease severity warrants initiation of a LABA.
No FDA black box warning exists for this drug.
Asthma-related death,Deterioration of disease,Use of anti-inflammatory agents,Paradoxical bronchospasm,Cardiovascular effects,Hypokalemia,Hyperglycemia,Immediate hypersensitivity reactions
Theophylline has a narrow therapeutic index; serum levels must be monitored to avoid toxicity. Toxicity can include seizures, cardiac arrhythmias, and death. Caution in patients with heart failure, hepatic impairment, or those over 55 years. Risk of toxicity increased by concurrent medications such as cimetidine, fluoroquinolones, and macrolides.
Treatment of status asthmaticus or other acute episodes of asthma,Hypersensitivity to formoterol fumarate or any inactive ingredients
Hypersensitivity to theophylline or any component of the formulation; active seizure disorder; untreated cardiac arrhythmias; severe hypertension; hyperthyroidism; peptic ulcer disease; caution with concurrent use of ephedrine or other sympathomimetics.
No known food interactions. Formoterol may increase blood glucose, so monitor if diabetic. Avoid high-fat meals if using with certain devices? Not applicable.
High-fat meals may delay absorption. Avoid charcoal-grilled foods and large amounts of caffeine. Grapefruit juice may increase theophylline levels; limit intake.
Formoterol fumarate (FORADIL CERTIHALER) is classified as FDA Pregnancy Category C. In animal studies, formoterol caused fetal malformations (e.g., omphalocele, skeletal abnormalities) at high systemic exposures. There are no adequate well-controlled studies in pregnant women. Risk to fetus cannot be ruled out; use only if potential benefit justifies potential risk. First trimester: limited data, theoretical risk based on animal findings. Second and third trimesters: may cause uterine relaxation and delay labor; avoid use near term unless clearly needed.
Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypoglycemia, and reduced uterine contractility; avoid use near term due to potential for neonatal bradycardia and hypoglycemia.
It is unknown if formoterol is excreted in human breast milk. No M/P ratio available. In lactating rats, formoterol was detected in milk. Because many drugs are excreted in human milk, caution is advised. Decision to discontinue nursing or drug should consider importance of drug to mother. Consider alternative therapies with more breastfeeding safety data.
Salbutamol is excreted into breast milk in minimal amounts; estimated infant dose <2% of maternal weight-adjusted dose. No known adverse effects in nursing infants. M/P ratio not established. Use with caution.
No specific dose adjustments recommended for pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, clearance) may reduce systemic exposure, but standard dosing is generally maintained. Use lowest effective dose to control asthma. Avoid use during labor and delivery due to tocolytic effect.
No dose adjustment required for inhaled salbutamol. Increased clearance in late pregnancy may necessitate higher doses for systemic effects; monitor clinical response and adjust accordingly.
Formoterol is a long-acting beta-agonist (LABA) with rapid onset (within 5 minutes). Must not be used as monotherapy for asthma without concomitant inhaled corticosteroid. Do not use for acute bronchospasm; short-acting beta-agonists are preferred. Rinse mouth after inhalation to prevent thrush and hoarseness. Monitor for paradoxical bronchospasm, tachyphylaxis, and cardiovascular effects. Can be used once or twice daily depending on formulation.
AEROLATE SR contains theophylline; narrow therapeutic index (10-20 mcg/m L). Monitor serum levels, especially with CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) or inducers (e.g., carbamazepine, phenytoin). SR formulation avoids peak-trough fluctuations; do not crush or chew. Caution in heart failure, hepatic impairment, and elderly.
Do not use Foradil Certihaler to relieve sudden breathing problems; always have a rescue inhaler (e.g., albuterol) available.,Use exactly as prescribed; do not skip doses or use more than prescribed.,Rinse your mouth with water after each use to prevent mouth infection and hoarseness.,Tell your doctor if you have heart problems, high blood pressure, seizures, or thyroid disease.,If asthma, always use this medication with an inhaled corticosteroid; never use LABA alone.,Seek medical help if your symptoms worsen or rescue inhaler does not work well.,Store at room temperature away from moisture and heat. Keep cap on when not in use.
Take exactly as prescribed; do not crush or chew the sustained-release tablet.,Do not stop suddenly; sudden withdrawal may worsen breathing.,Avoid excessive caffeine (coffee, tea, chocolate) as it may increase side effects.,Report nausea, vomiting, insomnia, palpitations, or seizures immediately.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FORADIL CERTIHALER vs AEROLATE SR, answered by our medical review team.
FORADIL CERTIHALER is a Bronchodilator that works by Formoterol is a long-acting beta2-adrenergic receptor agonist that stimulates intracellular adenyl cyclase, increasing cyclic AMP production and causing bronchodilation.. AEROLATE SR is a Bronchodilator that works by AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FORADIL CERTIHALER and AEROLATE SR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FORADIL CERTIHALER is: One inhalation (12 mcg) twice daily via oral inhalation.. The standard adult dose of AEROLATE SR is: 400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FORADIL CERTIHALER and AEROLATE SR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FORADIL CERTIHALER is classified as Category C. Formoterol fumarate (FORADIL CERTIHALER) is classified as FDA Pregnancy Category C. In animal studies, formoterol caused fetal malformations (e.g., omphalocele, skeletal abnormalit. AEROLATE SR is classified as Category C. Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.